Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "CTLA-4 Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive overview of more ...
Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate ...
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...
UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development. New Jersey-based UroGen forked ...
A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile. Analysts got an ...
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers at Salk Institute for Biological Studies ...
SUZHOU, China, Feb. 15, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results